Patients should be aware of adverse reactions occurring during entrectinib use. If symptoms are severe, consult a doctor promptly for dosage adjustment.
1. Serious Adverse Reactions
Congestive Heart Failure: In clinical studies, some patients experienced congestive heart failure, some of which were grade 3. The median time to onset was 2 months. Some patients needed to temporarily discontinue or stop entrectinib, and some patients experienced symptom relief after treatment.
Central Nervous System Effects: These include cognitive impairment, mood disturbances, dizziness, and sleep disturbances. Some patients experienced cognitive impairment, mood disturbances, dizziness, and sleep disturbances. Some patients required dosage adjustment or discontinuation of the drug.
Bone Fractures: Fractures occurred in both adult and pediatric patients. Some fractures occurred after falls or other traumas, while some fractures in pediatric patients were not caused by trauma.
Hepatotoxicity: Some patients experienced elevated AST and ALT, with some experiencing grade 3-4 AST or ALT elevations. Some patients needed to temporarily discontinue or stop entrectinib.
Hyperuricemia: Some patients developed symptomatic hyperuricemia and grade 4 hyperuricemia, including one patient who died due to tumor lysis syndrome. Some patients require uric acid-lowering medication or dose adjustment.
QT Interval Prolongation: Some patients experienced QTcF interval prolongation >60ms and QTcF interval >500ms.
Visual Disorders: Some patients experienced visual changes, including blurred vision, photophobia, and diplopia.
2. Common Adverse Reactions (≥20%):
These include fatigue, constipation, taste disturbances, edema, dizziness, diarrhea, nausea, paresthesia, dyspnea, myalgia, cognitive impairment, weight gain, cough, vomiting, fever, arthralgia, and visual disturbances.
